Toxicity Studies of Poly(Anhydride) Nanoparticles as Carriers for Oral Drug Delivery
- 512 Downloads
To evaluate the acute and subacute toxicity of poly(anhydride) nanoparticles as carriers for oral drug/antigen delivery.
Three types of poly(anhydride) nanoparticles were assayed: conventional (NP), nanoparticles containing 2-hydroxypropyl-β-cyclodextrin (NP-HPCD) and nanoparticles coated with poly(ethylene glycol) 6000 (PEG-NP). Nanoparticles were prepared by a desolvation method and characterized in terms of size, zeta potential and morphology. For in vivo oral studies, acute and sub-acute toxicity studies were performed in rats in accordance to the OECD 425 and 407 guidelines respectively. Finally, biodistribution studies were carried out after radiolabelling nanoparticles with 99mtechnetium.
Nanoparticle formulations displayed a homogeneous size of about 180 nm and a negative zeta potential. The LD50 for all the nanoparticles tested was established to be higher than 2000 mg/kg bw. In the sub-chronic oral toxicity studies at two different doses (30 and 300 mg/kg bw), no evident signs of toxicity were found. Lastly, biodistribution studies demonstrated that these carriers remained in the gut with no evidences of particle translocation or distribution to other organs.
Poly(anhydride) nanoparticles (either conventional or modified with HPCD or PEG6000) showed no toxic effects, indicating that these carriers might be a safe strategy for oral delivery of therapeutics.
KEY WORDSbiodistribution nanoparticles oral poly(anhydride) toxicity
percentage of injected dose per gram
instant thin layer chromatography
mean corpuscular hemoglobin
mean corpuscular hemoglobin concentration
mean corpuscular volume
conventional poly(anhydride) nanoparticles
nanoparticles containing 2-hydroxypropyl-β-cyclodextrin
pegylated poly(anhydride) nanoparticles
poly(ethylene glycol) 6000
copolymer of methyl vinyl ether and maleic anhydride
red blood corpuscles count
single-photon emission computed tomography
white blood corpuscles count
ACKNOWLEDGMENTS AND DISCLOSURES
This work was supported by the Ministry of Science and Innovation in Spain (projects SAF2008-02538) and Caja Navarra Foundation (Grant 10828). Patricia Ojer was also financially supported by a grant from the Department of Education of the Gobierno de Navarra in Spain.
- 13.Organization for Economic Cooperation and Development. Nanosafety at the OECD: the First Five Years 2006–2010. Paris: OECD Publishing; 2011. Available from: http://www.oecd.org/dataoecd/6/25/47104296.pdf.
- 14.Organization for Economic Cooperation and Development. Preliminary review of OECD test guidelines for their applicability to manufactured nanomaterials. Paris: OECD; 2009. Vol. No. 15 - ENV/JM/MONO (2009)21.Google Scholar
- 23.Ojer P, Salman H, Da Costa Martins R, Calvo J, López de Cerain A, Gamazo C, et al. Spray-drying of poly(anhydride) nanoparticles for drug/antigen delivery. J Drug Del Sci Tech. 2010;20(5):353–9.Google Scholar
- 27.Organization for Economic Cooperation and Development. Test No. 425: acute oral toxicity: up-and-down procedure. Guidelines for the testing of chemicals. Paris: OECD; 2006.Google Scholar
- 28.Organization for Economic Cooperation and Development. Test No. 407: repeated dose 28-day oral toxicity study in rodents. Guidelines for the testing of chemicals. Paris: OECD; 2001.Google Scholar
- 30.Sharma NC, Galustians HJ, Qaquish J, Galustians A, Rustogi KN, Petrone ME, et al. The clinical effectiveness of a dentifrice containing triclosan and a copolymer for controlling breath odor measured organoleptically twelve hours after toothbrushing. J Clin Dent. 1999;10(4):131–4.PubMedGoogle Scholar
- 31.Andrews GP, Jones DS. Poly(methyl vinyl ether/maleic anhydride). In: Rowe RC, Sheskey PJ, Quinn ME, editors. Handbook of pharmaceutical excipients. 6th ed. Washington DC: American Pharmacists Association; 2009. p. 534–5. London: Pharmaceutical Press.Google Scholar
- 40.Hayes AW. Principles and methods of toxicology. 4th ed. Philadelphia: Taylor & Francis; 2001.Google Scholar